Nyrada Past Earnings Performance
Past criteria checks 0/6
Nyrada's earnings have been declining at an average annual rate of -5.1%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 7.8% per year.
Key information
-5.1%
Earnings growth rate
37.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 7.8% |
| Return on equity | -108.8% |
| Net Margin | -169.8% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Nyrada makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -5 | 3 | 0 |
| 30 Sep 23 | 2 | -6 | 3 | 0 |
| 30 Jun 23 | 1 | -8 | 3 | 0 |
| 31 Mar 23 | 2 | -6 | 3 | 0 |
| 31 Dec 22 | 2 | -4 | 3 | 0 |
| 30 Sep 22 | 2 | -4 | 3 | 0 |
| 30 Jun 22 | 1 | -4 | 3 | 0 |
| 31 Mar 22 | 2 | -4 | 3 | 0 |
| 31 Dec 21 | 2 | -4 | 4 | 0 |
| 30 Sep 21 | 2 | -4 | 4 | 0 |
| 30 Jun 21 | 2 | -4 | 3 | 0 |
| 31 Mar 21 | 2 | -5 | 4 | 0 |
| 31 Dec 20 | 1 | -6 | 5 | 0 |
| 30 Sep 20 | 1 | -6 | 5 | 0 |
| 30 Jun 20 | 1 | -6 | 5 | 0 |
| 31 Mar 20 | 1 | -5 | 4 | 0 |
| 31 Dec 19 | 0 | -4 | 3 | 0 |
| 30 Sep 19 | 0 | -4 | 3 | 0 |
| 30 Jun 19 | 0 | -4 | 3 | 0 |
Quality Earnings: NYR is currently unprofitable.
Growing Profit Margin: NYR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NYR is unprofitable, and losses have increased over the past 5 years at a rate of 5.1% per year.
Accelerating Growth: Unable to compare NYR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NYR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: NYR has a negative Return on Equity (-108.75%), as it is currently unprofitable.